Breaking News

BARDA Invests in Development of Antifungal Treatments

Seeks partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.

Author Image

By: Charlie Sternberg

Associate Editor

The Biomedical Advanced Research and Development Authority (BARDA) has taken action to add to the areas of interest in its new Broad Agency Announcement (BAA) the development of antifungal Medical Countermeasures (MCM) to treat infections caused by drug-resistant fungal threats.   For the first time, BARDA announced this week it is seeking partnerships to develop broad-spectrum next-generation antifungal drugs to treat high-priority fungal infections.   “It is extremely exciting to see BARDA...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters